EMA Withdrawn: Crixivan (indinavir sulfate ethanolate) — Merck Sharp & Dohme B.V.

View source ↗

Summary

Crixivan (indinavir sulfate ethanolate) has been withdrawn from EMA marketing authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Crixivan (indinavir)

Snippet

Status: Withdrawn. Therapeutic area: HIV Infections. MAH: Merck Sharp & Dohme B.V.. Decision date: 03/08/2018